Nasdaq seel.

Dec 4, 2023 · Ulysses Erickson. December 4, 2023. Marathon Digital Holdings Inc (NASDAQ:MARA) has a beta value of 5.11 and has seen 56.64 million shares traded in the last trading session. The company, currently valued at $3.05B, closed the last trade at $13.70 per share which meant it gained $1.73 on the day or 14.45% during that session. British American Tobacco could be the most diverse among these three companies. You see, it enjoys a breadth of products and markets it serves. The company …The technology sector, broadly speaking, is having a great year. The Nasdaq-100 tech index has jumped 47% so far, and it's now a stone's throw away from …About Real-Time Quotes. Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. The intraday chart, the last-five real-time quotes and sales data. Real-time ...This is the case with Michael Golembiewski, CFO of Seelos Therapeutics Inc (NASDAQ:SEEL), who recently bought 83,000 shares of the company on November 30, 2023. ... SEEL, is a clinical-stage ...

Mar 10, 2023 · NEW YORK, March 10, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ... - Seelos expects to release top-line data in two registrational studies in 2023. NEW YORK, May 15, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided a …Nasdaq BookViewer. A real-time view of all buy and sell order depth for The Nasdaq Stock Market. Achieve better trade performance by viewing all the buy and sell orders in Nasdaq for securities ...

Sep 21, 2023 · In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on Seelos Therapeutics, with a price target of $4.00. The company’s shares closed last Wednesday at $0.31, close ...

Seelos Therapeutics (NASDAQ: SEEL) stock is falling on Wednesday after the clinical-stage biopharmaceutical company priced a public offering of its shares. That public offering has Seelos ...Seelos Therapeutics, Inc. Common Stock (SEEL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. NASDAQ · Seelos Therapeutics Inc (SEEL). Seelos Therapeutics Inc (SEEL) Cotización. SEEL Seelos Therapeutics Inc. NASDAQ. 0.1591. 0.0291 (22.38%). Última ...NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares tumbled 12% to $2.3513 after the company priced 15.24 million share offering at $2.05 per share. Shares of Lipocine Inc. (NASDAQ: ...

(NASDAQ: SEEL) Seelos Therapeutics currently has 5,379,327 outstanding shares. With Seelos Therapeutics stock trading at $2.38 per share, the total value of ...

(NASDAQ: SEEL) Seelos Therapeutics currently has 127,365,359 outstanding shares. With Seelos Therapeutics stock trading at $0.17 per share, the total …

Seelos Therapeutics, Inc. Common Stock (SEEL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.The company’s shares are showing year-to-date downside of -81.37%, with the 5-day performance at -12.82% in the red. However, in the 30-day time frame, Seelos Therapeutics Inc (NASDAQ:SEEL) is -32.32% down. Looking at the short shares, we see there were 8.32 million shares sold at short interest cover period of 1.95 days.Home SEEL • NASDAQ. add. Share. Seelos Therapeutics Inc. $1.38. After Hours: ... ( 2.90%)+0.040. Closed: Dec 1, 7:47:15 PM GMT-5 · USD · NASDAQ · Disclaimer.NEW YORK, Oct. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...Find the latest Earnings Report Date for Alabama Power Co 4.72% PRF PERPETUAL USD 100 (SEEL) at Nasdaq.com.Seelos Therapeutics, Inc NASDAQ: SEEL is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in central ...

Seelos Therapeutics, Inc. Common Stock (SEEL) 0 Add to Watchlist Add to Portfolio Quotes Summary Real-Time Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is...Jan 24, 2019 · Seelos is expected to begin trading today, January 24, 2019, on The Nasdaq Capital Market under the ticker symbol “SEEL”. The previous ticker symbol was “APRI” (Nasdaq: APRI). NEW YORK, May 5, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...Find the latest dividend history for Alabama Power Co 4.72% PRF PERPETUAL USD 100 (SEEL) at Nasdaq.com.NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...NEW YORK, Sept. 20, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced top line data demonstrating clinically meaningful treatment effects across multiple endpoints and ...

Seelos Therapeutics, Inc. Common Stock (SEEL) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Fees for the Nasdaq Global Select Market and the Nasdaq Global Market are set higher. The entry fee is $270,000 with a $25,000 application fee. Subsequent annual fees range from $50,000 to $173,500.NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company provided an update on recent pipeline developments and corporate ...Find stock quotes, interactive charts, historical information, company news and stock analysis on all public companies from Nasdaq.NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided its clinical update for the second quarter ended June 30, 2023.British American Tobacco could be the most diverse among these three companies. You see, it enjoys a breadth of products and markets it serves. The company …24 nov 2023 ... (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central ...At the end of the first quarter of 2021, 11 hedge funds in the database of Insider Monkey held stakes worth $47 million in Seelos Therapeutics, Inc. (NASDAQ: SEEL), up from 4 in the preceding ...

NEW YORK, May 19, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS ...

NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...

Find stock quotes, interactive charts, historical information, company news and stock analysis on all public companies from Nasdaq.View live Seelos Therapeutics, Inc. chart to track its stock's price action. Find market predictions, SEEL financials and market news.Dec 4, 2023 · Micromobility.com Inc (NASDAQ:MCOM)’s Major holders. Insiders own 0.88% of the company shares, while shares held by institutions stand at 0.23% with a share float percentage of 0.23%. Investors are also buoyed by the number of investors in a company, with Micromobility.com Inc having a total of 18 institutions that hold shares in the company. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Jul 12, 2023 · Seelos Therapeutics ( NASDAQ: SEEL) is gearing up to report results from two studies before the end of 2023. The first catalyst deals with the release of results from part 2 of a phase 2 ... Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...24 nov 2023 ... NEW YORK, Nov. 24, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage ...Get the latest Seelos Therapeutics Inc (SEEL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Get the latest Seelos Therapeutics Inc (SEEL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …Cigna shares tumbled past 7%, and Humana fell 5.4%. Vivos Therapeutics ( VVOS) said Wednesday the US Food and Drug Administration has granted 510 (k) …NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided its clinical update for the second quarter ended June 30, 2023.Get real-time NASDAQ Last Sale Intraday Trade History Report, commonly referred to as "Time & Sales," shows the last-five real-time time and sales data for all of your favorite U.S. stocks (listed ...

We’ve looked before at Seelos Therapeutics: “Seelos Therapeutics (NASDAQ: SEEL) stock dropped 69% yesterday and a further 9% today. That’s 80% off SEEL stock in the one, slightly protracted, move. The reason why is the failure of the Phase II test. What might be worse is the reason for the failure. The observed results weren’t that bad ...Seelos Therapeutics, Inc. Common Stock (SEEL) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ...Instagram:https://instagram. health insurance companies in new yorksquare enix stockswhat old quarters are worth moneyhbi stocks 10 Sep, 2020, 09:00 ET. NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL ), a clinical-stage biopharmaceutical company focused on the development of therapies for ...Whether to protect a portfolio against a market correction, hedge risks, or generate yield enhancement, Nasdaq-100 index options give both retail and institutional investors the ability to stay ... investing in insuranceillm stock NEW YORK, May 15, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...NEW YORK, April 4, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ... nyse rtx financials Seelos Therapeutics, Inc. (NASDAQ:SEEL) is a New York-based clinical-stage biopharmaceutical company, focused on the development and commercialization of therapeutics for the central nervous ...NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided its clinical update for the second quarter ended June 30, 2023.